Pharmacological properties of bergapten: mechanistic and therapeutic aspects
Autor(a) principal: | |
---|---|
Data de Publicação: | 2022 |
Outros Autores: | , , , , , , , , , , , , , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/10198/26721 |
Resumo: | Bergapten (BP) or 5-methoxypsoralen (5-MOP) is a furocoumarin compound mainly found in bergamot essential oil but also in other citrus essential oils and grapefruit juice. This compound presents antibacterial, anti-inflammatory, hypolipemic, and anticancer effects and is successfully used as a photosensitizing agent. The present review focuses on the research evidence related to the therapeutic properties of bergapten collected in recent years. Many preclinical and in vitro studies have been evidenced the therapeutic action of BP; however, few clinical trials have been carried out to evaluate its efficacy. These clinical trials with BP are mainly focused on patients suffering from skin disorders such as psoriasis or vitiligo. In these trials, the administration of BP (oral or topical) combined with UV irradiation induces relevant lesion clearance rates. In addition beneficial effects of bergamot extract were also observed in patients with altered serum lipid profiles and in people with nonalcoholic fatty liver. On the contrary, there are no clinical trials that investigate the possible effects on cancer. Although the bioavailability of BP is lower than that of its 8-methoxypsoralen (8-MOP) isomer, it has fewer side effects allowing higher concentrations to be administered. In conclusion, although the use of BP has therapeutic applications on skin disorders as a sensitizing agent and as components of bergamot extract as hypolipemic therapy, more trials are necessary to define the doses and treatment guidelines and its usefulness against other pathologies such as cancer or bacterial infections. |
id |
RCAP_ced1aa39f5cd0000800dc114b2b544a8 |
---|---|
oai_identifier_str |
oai:bibliotecadigital.ipb.pt:10198/26721 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
|
spelling |
Pharmacological properties of bergapten: mechanistic and therapeutic aspects5-MethoxypsoralenAnti-inflammatory agentsHumansMethoxsalenOsteoporosisAnimalsBone resorptionDiabetes complicationsDisease ModelsAnimalMethoxsalenAdverse effectsPharmacokineticsBiological availabilityClinical TrialsBergapten (BP) or 5-methoxypsoralen (5-MOP) is a furocoumarin compound mainly found in bergamot essential oil but also in other citrus essential oils and grapefruit juice. This compound presents antibacterial, anti-inflammatory, hypolipemic, and anticancer effects and is successfully used as a photosensitizing agent. The present review focuses on the research evidence related to the therapeutic properties of bergapten collected in recent years. Many preclinical and in vitro studies have been evidenced the therapeutic action of BP; however, few clinical trials have been carried out to evaluate its efficacy. These clinical trials with BP are mainly focused on patients suffering from skin disorders such as psoriasis or vitiligo. In these trials, the administration of BP (oral or topical) combined with UV irradiation induces relevant lesion clearance rates. In addition beneficial effects of bergamot extract were also observed in patients with altered serum lipid profiles and in people with nonalcoholic fatty liver. On the contrary, there are no clinical trials that investigate the possible effects on cancer. Although the bioavailability of BP is lower than that of its 8-methoxypsoralen (8-MOP) isomer, it has fewer side effects allowing higher concentrations to be administered. In conclusion, although the use of BP has therapeutic applications on skin disorders as a sensitizing agent and as components of bergamot extract as hypolipemic therapy, more trials are necessary to define the doses and treatment guidelines and its usefulness against other pathologies such as cancer or bacterial infections.HindawiBiblioteca Digital do IPBQuetglas-Llabrés, Maria MagdalenaQuispe, CristinaHerrera-Bravo, JesúsCatarino, Marcelo D.Pereira, Olívia R.Cardoso, Susana M.Dua, KamalChellappan, Dinesh KumarPabreja, KavitaSatija, SaurabhMehta, MeenuSureda, AntoniMartorell, MiquelSatmbekova, DinaraYeskaliyeva, BalakyzSharifi-Rad, JavadRasool, NaeemButnariu, MonicaBagiu, Iulia CristinaBagiu, Radu VasileCalina, DanielaCho, William C.2023-02-01T11:10:50Z20222022-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10198/26721engQuetglas-Llabrés, Maria Magdalena; Quispe, Cristina; Herrera-Bravo, Jesús; Catarino, Marcelo D.; Pereira, Olívia R.; Cardoso, Susana M.; Dua, Kamal; Chellappan, Dinesh Kumar; Pabreja, Kavita; Satija, Saurabh; Mehta, Meenu; Sureda, Antoni; Martorell, Miquel; Satmbekova, Dinara; Yeskaliyeva, Balakyz; Sharifi-Rad, Javad; Rasool, Naeem; Butnariu, Monica; Bagiu, Iulia Cristina; Bagiu, Radu Vasile; Calina, Daniela; Cho, William C. (2022). Pharmacological properties of bergapten: mechanistic and therapeutic aspects. Oxidative Medicine and Cellular Longevity. ISSN 1942-0900. 2022, p. 1-101942-090010.1155/2022/86152421942-0994info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-02-08T01:24:31ZPortal AgregadorONG |
dc.title.none.fl_str_mv |
Pharmacological properties of bergapten: mechanistic and therapeutic aspects |
title |
Pharmacological properties of bergapten: mechanistic and therapeutic aspects |
spellingShingle |
Pharmacological properties of bergapten: mechanistic and therapeutic aspects Quetglas-Llabrés, Maria Magdalena 5-Methoxypsoralen Anti-inflammatory agents Humans Methoxsalen Osteoporosis Animals Bone resorption Diabetes complications Disease Models Animal Methoxsalen Adverse effects Pharmacokinetics Biological availability Clinical Trials |
title_short |
Pharmacological properties of bergapten: mechanistic and therapeutic aspects |
title_full |
Pharmacological properties of bergapten: mechanistic and therapeutic aspects |
title_fullStr |
Pharmacological properties of bergapten: mechanistic and therapeutic aspects |
title_full_unstemmed |
Pharmacological properties of bergapten: mechanistic and therapeutic aspects |
title_sort |
Pharmacological properties of bergapten: mechanistic and therapeutic aspects |
author |
Quetglas-Llabrés, Maria Magdalena |
author_facet |
Quetglas-Llabrés, Maria Magdalena Quispe, Cristina Herrera-Bravo, Jesús Catarino, Marcelo D. Pereira, Olívia R. Cardoso, Susana M. Dua, Kamal Chellappan, Dinesh Kumar Pabreja, Kavita Satija, Saurabh Mehta, Meenu Sureda, Antoni Martorell, Miquel Satmbekova, Dinara Yeskaliyeva, Balakyz Sharifi-Rad, Javad Rasool, Naeem Butnariu, Monica Bagiu, Iulia Cristina Bagiu, Radu Vasile Calina, Daniela Cho, William C. |
author_role |
author |
author2 |
Quispe, Cristina Herrera-Bravo, Jesús Catarino, Marcelo D. Pereira, Olívia R. Cardoso, Susana M. Dua, Kamal Chellappan, Dinesh Kumar Pabreja, Kavita Satija, Saurabh Mehta, Meenu Sureda, Antoni Martorell, Miquel Satmbekova, Dinara Yeskaliyeva, Balakyz Sharifi-Rad, Javad Rasool, Naeem Butnariu, Monica Bagiu, Iulia Cristina Bagiu, Radu Vasile Calina, Daniela Cho, William C. |
author2_role |
author author author author author author author author author author author author author author author author author author author author author |
dc.contributor.none.fl_str_mv |
Biblioteca Digital do IPB |
dc.contributor.author.fl_str_mv |
Quetglas-Llabrés, Maria Magdalena Quispe, Cristina Herrera-Bravo, Jesús Catarino, Marcelo D. Pereira, Olívia R. Cardoso, Susana M. Dua, Kamal Chellappan, Dinesh Kumar Pabreja, Kavita Satija, Saurabh Mehta, Meenu Sureda, Antoni Martorell, Miquel Satmbekova, Dinara Yeskaliyeva, Balakyz Sharifi-Rad, Javad Rasool, Naeem Butnariu, Monica Bagiu, Iulia Cristina Bagiu, Radu Vasile Calina, Daniela Cho, William C. |
dc.subject.por.fl_str_mv |
5-Methoxypsoralen Anti-inflammatory agents Humans Methoxsalen Osteoporosis Animals Bone resorption Diabetes complications Disease Models Animal Methoxsalen Adverse effects Pharmacokinetics Biological availability Clinical Trials |
topic |
5-Methoxypsoralen Anti-inflammatory agents Humans Methoxsalen Osteoporosis Animals Bone resorption Diabetes complications Disease Models Animal Methoxsalen Adverse effects Pharmacokinetics Biological availability Clinical Trials |
description |
Bergapten (BP) or 5-methoxypsoralen (5-MOP) is a furocoumarin compound mainly found in bergamot essential oil but also in other citrus essential oils and grapefruit juice. This compound presents antibacterial, anti-inflammatory, hypolipemic, and anticancer effects and is successfully used as a photosensitizing agent. The present review focuses on the research evidence related to the therapeutic properties of bergapten collected in recent years. Many preclinical and in vitro studies have been evidenced the therapeutic action of BP; however, few clinical trials have been carried out to evaluate its efficacy. These clinical trials with BP are mainly focused on patients suffering from skin disorders such as psoriasis or vitiligo. In these trials, the administration of BP (oral or topical) combined with UV irradiation induces relevant lesion clearance rates. In addition beneficial effects of bergamot extract were also observed in patients with altered serum lipid profiles and in people with nonalcoholic fatty liver. On the contrary, there are no clinical trials that investigate the possible effects on cancer. Although the bioavailability of BP is lower than that of its 8-methoxypsoralen (8-MOP) isomer, it has fewer side effects allowing higher concentrations to be administered. In conclusion, although the use of BP has therapeutic applications on skin disorders as a sensitizing agent and as components of bergamot extract as hypolipemic therapy, more trials are necessary to define the doses and treatment guidelines and its usefulness against other pathologies such as cancer or bacterial infections. |
publishDate |
2022 |
dc.date.none.fl_str_mv |
2022 2022-01-01T00:00:00Z 2023-02-01T11:10:50Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10198/26721 |
url |
http://hdl.handle.net/10198/26721 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
Quetglas-Llabrés, Maria Magdalena; Quispe, Cristina; Herrera-Bravo, Jesús; Catarino, Marcelo D.; Pereira, Olívia R.; Cardoso, Susana M.; Dua, Kamal; Chellappan, Dinesh Kumar; Pabreja, Kavita; Satija, Saurabh; Mehta, Meenu; Sureda, Antoni; Martorell, Miquel; Satmbekova, Dinara; Yeskaliyeva, Balakyz; Sharifi-Rad, Javad; Rasool, Naeem; Butnariu, Monica; Bagiu, Iulia Cristina; Bagiu, Radu Vasile; Calina, Daniela; Cho, William C. (2022). Pharmacological properties of bergapten: mechanistic and therapeutic aspects. Oxidative Medicine and Cellular Longevity. ISSN 1942-0900. 2022, p. 1-10 1942-0900 10.1155/2022/8615242 1942-0994 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Hindawi |
publisher.none.fl_str_mv |
Hindawi |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
|
repository.mail.fl_str_mv |
|
_version_ |
1777302008019025920 |